Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Action Packages Low On US FDA Priority List For Redaction And Posting

Executive Summary

Final review documents have been posted for only four of 12 biosimilars due to a backlog in applications considered the third priority level for redaction – a categorization that seems out of sync with the agency’s approach to labeling and its emphasis on promoting price competition.

You may also be interested in...



US FDA Ends Nearly 2-Year Drought In Biosimilar Action Package Postings

Posting of final review documents for three biosimilars – Cyltezo, Mvasi and Fulphila – brings to seven the number of licensed biosimilars for which action packages with underlying analytical and clinical data are publicly available. FDA has attributed posting delays to a backlog in the redaction queue but is not prioritizing postings based upon order of approval or commercial availability.

US FDA Ends Nearly 2-Year Drought In Biosimilar Action Package Postings

Posting of final review documents for three biosimilars – Cyltezo, Mvasi and Fulphila – brings to seven the number of licensed biosimilars for which action packages with underlying analytical and clinical data are publicly available. FDA has attributed posting delays to a backlog in the redaction queue but is not prioritizing postings based upon order of approval or commercial availability.

US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers

BIO and PhRMA want an exclusivity policy that protects subsequent changes to innovator biologics and oppose patent listings in the Purple Book; AAM says agency should waive unnecessary clinical bridging studies based on information provided under confidentiality agreements with foreign regulators.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel